Literature DB >> 10992454

Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum.

D M Okenu1, E M Riley, Q D Bickle, P U Agomo, A Barbosa, J R Daugherty, D E Lanar, D J Conway.   

Abstract

Invasion of human erythrocytes by Plasmodium falciparum merozoites is a multistep process. For many strains of the parasite, part of this process requires that the erythrocyte binding antigen 175 (EBA-175) of the merozoite binds to sialic acid residues of glycophorin A on the erythrocyte surface, a receptor-ligand interaction which represents a potential target for inhibition by antibodies. This study characterizes the reactivity of naturally acquired human antibodies with four recombinant proteins representing parts of EBA-175 (region II, regions III to V, and the dimorphic C and F segment region) in populations in which the organism is endemic. Serum immunoglobulin G (IgG) recognizing the recombinant proteins is predominantly of the IgG1 and IgG3 subclasses, and its prevalence increases with age. In a large population study in The Gambia, serum positivity for IgG or IgG1 and IgG3 subclass antibodies to each of the EBA-175 recombinant antigens was not significantly associated with subsequent protection from clinical malaria. However, there was a trend indicating that individuals with high levels of IgG to region II may have some protection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992454      PMCID: PMC101506          DOI: 10.1128/IAI.68.10.5559-5566.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Sequence conservation of a functional domain of erythrocyte binding antigen 175 in Plasmodium falciparum.

Authors:  B K Sim
Journal:  Mol Biochem Parasitol       Date:  1990-06       Impact factor: 1.759

2.  Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses.

Authors:  H Groux; J Gysin
Journal:  Res Immunol       Date:  1990 Jul-Aug

3.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

4.  Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion.

Authors:  M B Reed; S R Caruana; A H Batchelor; J K Thompson; B S Crabb; A F Cowman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

5.  Cloning of the Plasmodium vivax Duffy receptor.

Authors:  X D Fang; D C Kaslow; J H Adams; L H Miller
Journal:  Mol Biochem Parasitol       Date:  1991-01       Impact factor: 1.759

6.  Invasion of erythrocytes by Plasmodium falciparum malaria parasites: evidence for receptor heterogeneity and two receptors.

Authors:  G H Mitchell; T J Hadley; M H McGinniss; F W Klotz; L H Miller
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

7.  Erythrocyte receptor recognition varies in Plasmodium falciparum isolates.

Authors:  M E Perkins; E H Holt
Journal:  Mol Biochem Parasitol       Date:  1988-01-01       Impact factor: 1.759

8.  Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity.

Authors:  E M Riley; S J Allen; J G Wheeler; M J Blackman; S Bennett; B Takacs; H J Schönfeld; A A Holder; B M Greenwood
Journal:  Parasite Immunol       Date:  1992-05       Impact factor: 2.280

9.  Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion.

Authors:  B K Sim; P A Orlandi; J D Haynes; F W Klotz; J M Carter; D Camus; M E Zegans; J D Chulay
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

10.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes.

Authors:  H Bouharoun-Tayoun; P Attanath; A Sabchareon; T Chongsuphajaisiddhi; P Druilhe
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  42 in total

1.  Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children.

Authors:  Carlota Dobaño; Diana Quelhas; Llorenç Quintó; Laura Puyol; Elisa Serra-Casas; Alfredo Mayor; Tacilta Nhampossa; Eusebio Macete; Pedro Aide; Inacio Mandomando; Sergi Sanz; Sanjeev K Puniya; Bijender Singh; Puneet Gupta; Arindam Bhattacharya; Virander S Chauhan; John J Aponte; Chetan E Chitnis; Pedro L Alonso; Clara Menéndez
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen.

Authors:  Kevin K A Tetteh; David R Cavanagh; Patrick Corran; Rosemary Musonda; Jana S McBride; David J Conway
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea.

Authors:  Katharine R Trenholme; Craig S Boutlis; Rachel Kuns; Moses Lagog; Moses J Bockarie; Michelle L Gatton; David J Kemp; Michael F Good; Nicholas M Anstey; Donald L Gardiner
Journal:  Am J Trop Med Hyg       Date:  2005-06       Impact factor: 2.345

4.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

5.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

6.  Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Authors:  Gregory S Noland; Brett Hendel-Paterson; Xinan M Min; Ann M Moormann; John M Vulule; David L Narum; David E Lanar; James W Kazura; Chandy C John
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

7.  Population genetic analysis of large sequence polymorphisms in Plasmodium falciparum blood-stage antigens.

Authors:  Ambroise D Ahouidi; Amy K Bei; Daniel E Neafsey; Ousmane Sarr; Sarah Volkman; Dan Milner; Janet Cox-Singh; Marcelo U Ferreira; Omar Ndir; Zul Premji; Souleymane Mboup; Manoj T Duraisingh
Journal:  Infect Genet Evol       Date:  2009-11-30       Impact factor: 3.342

8.  Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems.

Authors:  Anjali Yadava; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

Review 9.  The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Authors:  Freya J I Fowkes; Jack S Richards; Julie A Simpson; James G Beeson
Journal:  PLoS Med       Date:  2010-01-19       Impact factor: 11.069

10.  Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort.

Authors:  N O Duah; D J C Miles; H C Whittle; D J Conway
Journal:  Parasite Immunol       Date:  2010-02       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.